Table 2.
Signal detection measures for the drugs of interest
| Anticoagulants and antiplatelets | RRR | PRR | 95% Lower limit PRR | 95% Upper limit PRR | Signal by frequentist approach | Number of reports | IC025 | EBGM05 | Signal by Bayesian approach |
|---|---|---|---|---|---|---|---|---|---|
| Antiplatelet drugs alone | |||||||||
| Acetylsalicylic acid | 3.5 | 3.5 | 3.4 | 3.6 | Positive | 3098 | 1.7 | 3.4 | Positive |
| Clopidogrel | 8.9 | 9.1 | 9 | 9.2 | 12,897 | 3.1 | 8.7 | ||
| Dual antiplatelets | |||||||||
| Acetylsalicylic acid with clopidogrel | 4.9 | 4.9 | 4.8 | 5.1 | Positive | 3820 | 2.2 | 4.7 | Positive |
| Triple antithrombotic therapies (with acetylsalicylic acid and clopidogrel) | |||||||||
| Acenocoumarol | 12.7 | 12.7 | 9.9 | 16.4 | Positive | 16 | 1.4 | 5 | Positive |
| Apixaban | 7.7 | 7.7 | 6.4 | 9.3 | 62 | 2.1 | 5.6 | ||
| Dabigatran | 10.9 | 10.9 | 9.7 | 12.3 | 106 | 2.5 | 8 | ||
| Rivaroxaban | 14.1 | 14.1 | 13.3 | 14.9 | 241 | 2.9 | 10.6 | ||
| Warfarin | 8.6 | 8.6 | 8.1 | 9.2 | 386 | 2.7 | 7.5 | ||
PRR: Proportional reporting ratio; RRR: Relative reporting ratio; IC: Information component; and EBGM: Empirical Bayes geometric mean